@article{dda0c87262134d2c9a841f5955ddaca2,
title = "Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia",
abstract = "We hypothesized that higher Charlson comorbidity index (CCI) predicts worse 1-month mortality and overall survival (OS) in patients ≥60 years with acute myeloid leukemia (AML). In our National Cancer Database study, patients with CCI 0 were more likely to receive chemotherapy and undergo upfront hematopoietic cell transplantation. One-month mortality and OS were significantly worse with CCI 1 or ≥2, compared with CCI 0.",
keywords = "Acute leukemia, Chemotherapy, Geriatrics, Older adults, Survival",
author = "Prajwal Dhakal and Valerie Shostrom and Al-Kadhimi, {Zaid S.} and Maness, {Lori J.} and Krishna Gundabolu and Bhatt, {Vijaya Raj}",
note = "Funding Information: V.R. Bhatt reports receiving consulting fees from Agios, Incyte, Omeros, Takeda, Partnership for Health Analytic Research, LLC and AbbVie; research funding (institutional) from Incyte, Jazz, Tolero Pharmaceuticals, Inc, and National Marrow Donor Program; and drug support for a trial from Oncoceutics. K. Gundabolu reports receiving consulting fees from Pfizer, Novartis, and Shionogi, and has stock in Portola Pharmaceuticals. All other authors state that they have no conflicts of interest.The National Cancer Data Base (NCDB) is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in the study are derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used or the conclusions drawn from these data by the investigators. The project described was supported by the National Institute of General Medical Sciences, 1U54GM115458-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. An abstract of this study was accepted for online publication by the 2020 American Society of Clinical Oncology Annual Meeting committee. Funding Information: The project described was supported by the National Institute of General Medical Sciences , 1U54GM115458-01 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: V.R. Bhatt reports receiving consulting fees from Agios, Incyte, Omeros, Takeda, Partnership for Health Analytic Research, LLC and AbbVie; research funding (institutional) from Incyte , Jazz , Tolero Pharmaceuticals, Inc , and National Marrow Donor Program ; and drug support for a trial from Oncoceutics . K. Gundabolu reports receiving consulting fees from Pfizer, Novartis, and Shionogi, and has stock in Portola Pharmaceuticals. All other authors state that they have no conflicts of interest. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = dec,
doi = "10.1016/j.clml.2020.07.002",
language = "English (US)",
volume = "20",
pages = "804--812.e8",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "12",
}